Fewer than one in 10 patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the global health agency as it publishes its inaugural advice on the therapies.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for broader and more equitable availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The new guidelines recognises that obesity is a chronic disease that can be treated with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant hurdles to universal availability to the treatments that can help people shift substantial weight, says the organization.
Skinny Jab Scarcity
Even in the present most optimistic outlook, the supply of GLP-1 therapies could only cover around 100 million people – under 10% of eligible patients, as stated by the WHO.
The advice urges governments and firms to expand availability, by approaches such as voluntary licensing.
Exclusive production rights on a key compound – the core ingredient of a leading brand – is due to expire in multiple nations in 2026.
The Way Obesity Jabs Function
These medications replicate a biological compound to delay gastric emptying, curb appetite and increase satiety so people reduce food intake.
Individuals commonly start to lose weight in the initial weeks of beginning the weekly injections.
Research indicates people may put most of the weight back on a year later of halting the medication, when their typical food cravings resume.
Being overweight or obese increases your chance for experiencing health problems, including diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight concerns people in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
